TOVX Theriva Biologics, Inc.

NYSE therivabio.com


$ 0.34 $ -0.09 (-20.92 %)    

Monday, 20-Oct-2025 19:53:29 EDT
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 0.333
$ 0.39
$ 0.32 x 1,000
$ 0.43 x 10
$ 0.32 - $ 0.40
$ 0.32 - $ 2.64
9,714,941
na
3.2M
$ 1.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-25-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-16-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 02-20-2020 12-31-2019 10-K
24 11-04-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 02-22-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-02-2017 12-31-2016 10-K
36 11-01-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 theriva-biologics-secures-4m-via-immediate-exercise-of-736m-warrants-at-054share-offers-investors-1472m-new-warrants-at-same-price

Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing t...

 theriva-biologics-to-present-vcn-12-and-vcn-01-preclinical-data-at-esgct-highlighting-novel-antitumor-mechanism-and-intracranial-feasibility-for-brain-tumors

- Preclinical data for VCN-12, the next candidate from Theriva's VCN-X discovery program, highlight a novel mechanism of ac...

 stock-market-today-nasdaq-sp-500-futures-gain-on-3rd-day-of-government-shutdownrumble-riggeti-kodiak-in-focus-updated

U.S. stock futures advanced on Friday following Thursday's record advances. Futures of major benchmark indices were higher.

 rumble-xcel-brands-and-3-stocks-to-watch-heading-into-friday

US stock futures up, Actelis Networks, XCel Brands, Rumble Inc. up after hours. Theriva Biologics to cut workforce, Open Text t...

 theriva-biologics-cuts-32-of-workforce-in-restructuring-to-focus-on-cancer-drug-development-and-regulatory-strategy-expects-will-extend-its-cash-runway-into-q2-of-2026

Item 2.05 Costs Associated with Exit or Disposal Activities. On September 28, 2025, the Board of Directors of Theriva Biologics...

 theriva-biologics-has-received-a-notice-of-allowance-for-a-us-patent-titled-alkaline-phosphatase--formulations-for-the-treatment-of-microbiome-related-diseases

https://patentcenter.uspto.gov/applications/18744950/ifw/docs

 theriva-biologics-q2-eps-193-misses-108-estimate

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1...

 theriva-biologics-to-present-data-from-vcn-01-retinoblastoma-phase-1-clinical-trial-at-asco-2025-announces-investigator-meeting-to-review-topline-data-from-virage-phase-2b-trial-of-vcn-01-in-metastatic-pancreatic-cancer

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION